Ligand to acquire Metabasis
This article was originally published in Scrip
Executive Summary
Ligand Pharmaceuticals has stepped in to salvage what is left of Metabasis Therapeutics by agreeing to acquire the beleaguered firm for $3.2 million in cash. Both companies' boards of directors have unanimously approved the deal.